DrugPatentWatch Database Preview

Celgene Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

CELGENE has seven approved drugs.

There are forty-eight US patents protecting CELGENE drugs.

There are six hundred and eighty-two patent family members on CELGENE drugs in fifty-one countries and twenty-seven supplementary protection certificates in thirteen countries.

International Patents:	682
US Patents:	48
Tradenames:	7
Ingredients:	7
NDAs:	7
Patent Litigation for Celgene:	See patent lawsuits for Celgene
PTAB Cases with Celgene as patent owner:	See PTAB cases with Celgene as patent owner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No	8,455,536	Start Trial				Start Trial
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013		RX	Yes	No	8,530,498	Start Trial				Start Trial
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes	6,869,399	Start Trial				Start Trial
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-003	Mar 21, 2014		RX	Yes	Yes	9,724,330	Start Trial				Start Trial
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-002	Mar 21, 2014		RX	Yes	No	8,455,536	Start Trial				Start Trial
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-001	Feb 8, 2013		RX	Yes	No	6,755,784	Start Trial				Start Trial
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes	8,626,531	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-003	Jun 29, 2006	6,281,230	Start Trial
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013	8,158,653	Start Trial
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	8,204,763	Start Trial
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	5,629,327	Start Trial
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013	6,316,471	Start Trial
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	6,045,501	Start Trial
Celgene	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	8,204,763	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2105135	92642	Luxembourg	Start Trial	PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805
2105135	212 50002-2015	Slovakia	Start Trial	PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
2105135	122015000013	Germany	Start Trial	PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
2105135	C20150005 00140	Estonia	Start Trial	PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
2105135	300717	Netherlands	Start Trial	PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
0925294	07C0056	France	Start Trial	PRODUCT NAME: LENALIDOMIDE; REGISTRATION NO/DATE: EU/1/07/391/001-004 20070618
0925294	SPC033/2007	Ireland	Start Trial	SPC033/2007: 20080507, EXPIRES: 20220613
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.